Tg Therapeutics (TGTX) Receivables (2014 - 2026)

Tg Therapeutics' Receivables history runs 7 years deep, the most recent figure standing at $392.0 million for Q1 2026.

• In Q1 2026, Receivables rose 2825.72% year-over-year to $392.0 million; the TTM figure through Mar 2026 stood at $392.0 million (up 2825.72% YoY), while the FY2025 annual figure was $305.6 million, up 100.17% from the prior year.
• Receivables was $392.0 million for Q1 2026 at Tg Therapeutics, up from $305.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $392.0 million in Q1 2026 to a low of $88000.0 in Q2 2022.
• Historically, Receivables has averaged $117.4 million across 5 years, with a median of $71.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables slumped 90.55% in 2022, then jumped 19768.18% in 2023.
• A 5-year view of Receivables shows it stood at $88000.0 in 2022, then surged by 64664.77% to $57.0 million in 2023, then jumped by 167.9% to $152.7 million in 2024, then surged by 100.17% to $305.6 million in 2025, then gained by 28.28% to $392.0 million in 2026.
• The last three Receivables figures came in at $392.0 million (Q1 2026), $305.6 million (Q4 2025), and $265.4 million (Q3 2025), per Business Quant data.